The order follows a recent recommendation that LuViva be included as an alternative to the Pap test at the 22nd Annual Scientific Meeting of the Society of Obstetricians and Gynecologists of Indonesia.

The order brings to 14 the number of LuVivas and almost 7,000 the number of disposable Cervical Guides sold to Indonesia.

“We believe that the recommendation to include LuViva as an alternative to the Pap test will have a very positive effect for the product in Indonesia, the fourth most populous market in the world,” said Gene Cartwright, CEO and President of Guided Therapeutics, Inc.

“Cervical cancer is the second most common malignancy among women of Indonesia with an incidence rate of about 17 in 100,000. In Indonesia, 70% of cervical cancer cases diagnosed are in the advanced stage, there is a clear unmet need to increase screening to detect cervical disease before it develops into cancer.”

In Indonesia, more than 93 million women are at risk of developing cervical cancer. Less than 25% of women aged 30 to 50 are screened for cervical cancer in Indonesia with the primary method of visual inspection with acetic acid.

There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.